<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5367">
  <stage>Registered</stage>
  <submitdate>20/10/2015</submitdate>
  <approvaldate>20/10/2015</approvaldate>
  <nctid>NCT02592369</nctid>
  <trial_identification>
    <studytitle>CoreValve Evolut R FORWARD Study</studytitle>
    <scientifictitle>The Medtronic CoreValve Evolut R FORWARD Study</scientifictitle>
    <utrn />
    <trialacronym>FORWARD</trialacronym>
    <secondaryid>Evolut Râ„¢ FORWARD Study</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Aortic Valve Stenosis</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Medtronic CoreValve Evolut R System

Treatment: devices: Medtronic CoreValve Evolut R System
The Evolut R System is intended for relief of aortic stenosis in patients with symptomatic heart disease due to severe native calcific aortic stenosis who are judged by a heart team, to be at high or extreme risk for open heart surgery. The Evolut R TAV treats aortic stenosis by displacing and functionally replacing the dysfunctional native valve with a bioprosthetic valve delivered on a catheter while the heart is still beating, thus avoiding the risks of cardiopulmonary bypass. Its intended performance is to relieve aortic valve stenosis without inducing significant regurgitation, thereby restoring effective aortic valve function.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>All-cause mortality rate - All-cause mortality rate at 30 days post procedure</outcome>
      <timepoint>30 days post implant</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Device success according to VARC2 - Device success rate at 24 hours to 7 days, defined according to the Valve Academic Research Consortium-2 (VARC-2) guidelines as:
Absence of procedural mortality, AND
Correct positioning of a single prosthetic heart valve into the proper anatomical location, AND
Intended performance of the prosthetic heart valve, defined as the absence of patient-prosthesis mismatch and mean gradient &lt; 20 mmHg (or peak velocity &lt; 3 m/sec), AND No moderate or severe prosthetic valve regurgitation.</outcome>
      <timepoint>24h to 7 days post implant</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hemodynamic performance - Hemodynamic performance at 24 hours to 7 days (discharge) and 1 year post procedure, including the mean prosthetic valve gradient as measured by transthoracic echocardiography (TTE) and assessed by an independent core laboratory.</outcome>
      <timepoint>24h to 7 days and 1 year post implant</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hemodynamic performance - Hemodynamic performance at 24 hours to 7 days (discharge) and 1 year post procedure, including the effective orifice area as measured by transthoracic echocardiography (TTE) and assessed by an independent core laboratory.</outcome>
      <timepoint>24h to 7 days and 1 year post implant</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hemodynamic performance - Hemodynamic performance at 24 hours to 7 days (discharge) and 1 year post procedure, including the degree of prosthetic valve regurgitation (transvalvular, paravalvular, and total) as measured by transthoracic echocardiography (TTE) and assessed by an independent core laboratory.</outcome>
      <timepoint>24h to 7 days and 1 year post implant</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Early safety composite endpoint according to VARC2 - Early Safety composite endpoint at 30 days post procedure, defined according to the VARC-2 guidelines, defined as any of the following components:
All-cause mortality
All stroke (disabling and non-disabling)
Life-threatening bleeding
Acute kidney injury: stage 2 or 3 (including renal replacement therapy)
Coronary artery obstruction requiring intervention
Major vascular complication
Valve-related dysfunction requiring repeat procedure (BAV, TAVI, or SAVR)</outcome>
      <timepoint>30 days post implant</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Event rates according to VARC2 - Event rates of the individual components of the VARC-2 composite Early Safety endpoint at 30 days post procedure</outcome>
      <timepoint>30 days post implant</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rate of new permanent pacemaker implant - Rate of new permanent pacemaker implant at 30 days post procedure</outcome>
      <timepoint>30 days post implant</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Symptomatic native aortic valve stenosis or a stenosed, insufficient, or combined
             surgical bioprosthetic valve failure necessitating valve replacement

          -  Acceptable candidate for elective treatment with the Evolut R System and in conformity
             with the local regulatory and medico economic context

          -  Age =80 years OR considered to be at high or greater risk for surgical aortic valve
             replacement (AVR) where high risk is defined as:

               -  Society of Thoracic Surgeons (STS) predicted risk of mortality =8% OR

               -  Documented heart team agreement of risk for AVR due to frailty or comorbidities.

          -  Geographically stable and willing to return to the implanting site for all follow-up
             visits

          -  Of legal age to provide informed consent (patient Informed Consent or Data Release
             Form) in the country where they enroll in the trial

          -  The patient has been informed of the nature of the study, is able and willing to
             provide consent without assistance from a legal representative and has consented to
             participate, and has authorized the collection and release of his/her medical
             information by signing a Patient Informed Consent or Data Release Form.</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Known hypersensitivity or contraindication to aspirin, heparin (HIT/HITTS) and
             bivalirudin, ticlopidine, clopidogrel, Nitinol (Titanium or Nickel), or sensitivity to
             contrast media, which cannot be adequately premedicated

          -  Preexisting mechanical heart valve in aortic position

          -  Ongoing sepsis, including active endocarditis

          -  Anatomically not suitable for the Evolut R system

          -  Estimated life expectancy of less than 1 year

          -  Participating in another trial that may influence the outcome of this trial

          -  Need for emergency surgery for any reason</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>1061</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/04/2020</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Flinders Medical Centre - Adelaide</hospital>
    <hospital>Monash Medical Centre - Melbourne</hospital>
    <hospital>The Alfred Hospital - Melbourne</hospital>
    <hospital>Fiona Stanley Hospital Perth - Perth</hospital>
    <postcode> - Adelaide</postcode>
    <postcode> - Melbourne</postcode>
    <postcode> - Perth</postcode>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Antwerpen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Montreal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Toronto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Vancouver</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Cali</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Trinec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Creteil</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Massy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bad Oeynhausen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bonn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Cottbus</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dresden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Duesseldorf</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Karlsruhe</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Athens</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel-Aviv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Brescia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Catania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pisa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Eindhoven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Nieuwegein</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Oslo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Panama</country>
      <state>Panama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warsaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Vila Nova de Gaia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Saudi Arabia</country>
      <state>Riyadh</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Cape Town</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Malaga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Oviedo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Santiago de Compostela</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Uppsala</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Bern</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Zurich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Belfast</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Brighton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leeds</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Wolverhampton</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Medtronic Cardiovascular</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Prospective, single arm, multi-center, observational, post market study to document the
      clinical and device performance outcomes of the Evolut R system used in routine hospital
      practice in a large patient cohort for the treatment of symptomatic native aortic valve
      stenosis or a stenosed, insufficient, or combined surgical bioprosthetic valve failure
      necessitating valve replacement.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02592369</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Eberhard Grube, Prof. Dr.</name>
      <address>University Hospital, Bonn</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>